Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.56 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433755 | 0.89 | MYC (0.56) | HCAR3CASP6TSHRTTRLMNA | |
| SCHEMBL2366810 | 0.87 | HCAR3 (0.61) | PLA2G4BHCAR3CASP6TSHRTTR | |
| SCHEMBL106740 | 0.86 | ALDH1A1 (0.52) | PRSS1LMNAMAPTMEN1HPGD | |
| SCHEMBL1402203 | 0.85 | MAPT (0.65) | PLA2G4BHCAR3CASP6TSHRPRSS1 | |
| Hydrochloric Acid SCHEMBL11776063 | 0.84 | MAPT (0.64) | PLA2G4BHCAR3CASP6TSHRPRSS1 | |
| SCHEMBL176357 | 0.83 | TTR (0.68) | HCAR3CASP6TSHRTTRLMNA | |
| SCHEMBL177201 | 0.83 | PLA2G4B (0.65) | PLA2G4BHCAR3CASP6TSHRPRSS1 | |
| SCHEMBL1185562 | 0.83 | ALDH1A1 (0.50) | TSHRPRSS1LMNAMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL9775617 | 0.82 | TTR (0.67) | CASP6TSHRTTRLMNAMAPT | |
| SCHEMBL1749792 | 0.82 | PLA2G4B (0.74) | PLA2G4BHCAR3PRSS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459215-B | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmacy acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2016-03-02 | — | — | CN | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| CN-102459215-A | 3- (4-aminophenyl) -2-furancarboxylic acid derivatives and pharmaceutically acceptable salts thereof | DAINIPPON SUMITOMO PHARMA CO | 2012-05-16 | — | — | CN | disclosed |
| EP-2431362-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2431362-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2011007722-A1 | 3-SUBSTITUTED-2-FURANCARBOXYLIC ACID HYDRAZIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010131669-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | PLA2G4B 2246/4885HCAR3 320/4885CASP6 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.